France to Test Medical Cannabis for Two Years

Foley Hoag LLP - Cannabis and the Law
Contact

Foley Hoag LLP - Cannabis and the Law

Cannabis consumption is a complex issue and is first and foremost a health matter. While it is forbidden in France for recreational or medical use, on October 25, 2019 the French Parliament (National Assembly) gave its consent to conduct an experimentation on medical use of cannabis starting in early 2020.

The French National Agency for Safety of the Medicinal products (ANSM) had already approved the initiative in July 2019, in addition to 17 others EU Member States.

The experimentation is scheduled to last two years, including a 6-month phase-in period, a 6-month inclusion period to enroll patients, a 6-month period for patients monitoring and a 6-month period of data analysis. A final report will then be established and released by a scientific committee.

Three thousand patients, for whom no further therapeutic options are available, are expected to be monitored in order to assess whether cannabis derivatives have a positive impact on five specific diseases and symptoms:

  1. Refractory neuropathic pains,
  2. Some form of severe pharmacoresistant epilepsy,
  3. Supportive care in palliative treatment in oncology,
  4. Painful spasticity in case of multiple sclerosis,
  5. Others Central nervous system pathologies.

The ANSM has opted for a broad administration of the medicinal treatment such as oils, dried flowers, infusions or pills. The inhalation therapy is not included.

The question of the supply chain remains, as France does not authorize the production of cannabis.

The experimentation will be conducted in several healthcare facilities, in particular those that are reference centers for the pathologies above mentioned. The patient will first have to seek supplies in hospital pharmacy and then refill their prescriptions in a local pharmacy.

Nowadays, there are only two medicines with these active ingredients available in France. However, their heavy prescription requirements make them unavailable.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley Hoag LLP - Cannabis and the Law | Attorney Advertising

Written by:

Foley Hoag LLP - Cannabis and the Law
Contact
more
less

Foley Hoag LLP - Cannabis and the Law on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.